Evaluation and Performance Measures: 5.0 Network Development Measures
Operational Intent: These performance measures examine the activities that have been implemented to achieve the following outcomes:
- Support continued planning, development, and implementation of a national system forspecial pathogen patient care[4], including engaging state and jurisdiction special pathogen treatment centers; and other health care facilities (including but not limited to settings such as nursing homes, residential care facilities, EMS, and 911 call centers)
- Support NETEC in their activities as a 'force amplifier' in their region
Required Program Performance Measure | Data Point(s) | Data Entity | Calculation |
|---|---|---|---|
PM 8: Promising practices developed to support the continued planning, development, and system for special pathogen patient care | What promising practices have you developed to help achieve the continued planning, development, national system for special pathogen patient care using RESPTC FY21 Administrative Supplement funds? What impact did you achieve? (Free response – 750 character response length) | RESPTC | Qualitative description of promising impact achieved |
| PM 9: Challenges encountered by RESPTCs in the continued planning, development, and implementation of a national system for special pathogen patient care | What specific challenges have you encountered regarding your ability to plan, develop, and implement a national system for special pathogen care across sites? (Select all that apply)
Please briefly describe the impact of these challenges (free response – 600-character response length) | RESPTC | Number of RESPTCs reporting each challenge Qualitative description of challenges and impact of challenges |
| PM 10: Promising practices implemented by RESPTCs to access and use information and resources from NETEC | Which of the following promising practices did your RESPTC employ to access and use NETEC information and resources using RESPTC FY21 Administrative Supplement funds? (Select all that apply)
| RESPTC | Number of RESPTCs implementing each listed promising practice
|
| PM 11: Promising practices used that promote coordination and collaboration between RESPTCs and other regional disaster response organizations[6] | What promising practices did your organization use to collaborate with other regional organizations for disaster response (e.g., Regional Disaster Health Response System demonstration sites, Health Care Coalitions, etc.) using RESPTC FY21 Administrative Supplement R funds? What impact did you achieve? (Free response – 750-character response length) | RESPTC | Qualitative description of promising practices, partners, and impact achieved |
| PM 12: Promising practices associated with RESPTC initiatives to support the region's special pathogen system of care | What promising practices did your organization use to support the region's special pathogen system of care using RESPTC FY21 AdministrativeSupplement funds? What impact did you achieve? (Free response – 750-character response length) | RESPTC | Number of RESPTCs implementing initiatives Qualitative description of initiatives and impact achieved |
| PM 13: Challenges encountered during implementation of RESPTC initiatives that support the region's special pathogen system of care | What specific challenges have you encountered regarding implementation of regional treatment center initiatives to support your region's special pathogen system of care using RESPTC FY21 Administrative Supplement funds? What were the impacts of these challenges? (Free response – 750-character response length) | RESPTC | Number of RESPTCs reporting challenges Qualitative description of challenges and impact of challenges |
4. Funding for RESPTCs in FY21 built on previous Ebola programming, which specified this activity at the regional level. Due to the COVID-19 pandemic, ASPR sought to evolve the regional system already established through Ebola funding into a National Special Pathogen System (NSPS). In order to capture the true intent of RESPTCs' role in this system, this document refers to a "national system for special pathogen patient care." RESPTCs continue to operate regionally within this national system.
5. The Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities cooperative agreement (CFDA #93.817) Part B permits Regional Ebola and Other Special Pathogen Treatment Centers to participate in clinical research, clinical trials, and experimental protocols, if appropriate, but recipients may not use cooperative agreement funds for research.
6. Note: A similar question appears in performance measures for the RESPTC COVID-19 Preparedness and Response Activities Administrative Supplement. Please limit this particular response to activities and outcomes funded by the RESPTC FY21 Administrative Supplement.